A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes
Sponsor: argenx
Listed as NCT06436742, this PHASE1 trial focuses on CMS and Congenital Myasthenic Syndrome and remains actively recruiting participants. Sponsored by argenx, it has been updated 9 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- argenx
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Belfast, United Kingdom
- • Chicago, United States
- • Marseille, France
- • Milan, Italy
- • Ottawa, Canada
- • Oxford, United Kingdom
- • Paris, France
- • Sacramento, United States
- • Valencia, Spain